MicroPort Scientific Corporation Announces Potential Disposal of Equity Interest in Shanghai MicroPort Orthopedics to Tinavi
Key Highlights of the Transaction
- Potential Disposal: MicroPort Scientific Corporation (the Company, HKEX: 00853) has announced a significant transaction involving the potential disposal of up to 62% equity interest in its subsidiary, Shanghai MicroPort Orthopedics Co., Ltd. (the Target Company), to Tinavi Medical Technologies Co., Ltd. (SSE: 688277.SH) (Tinavi).
- Major Stake Sale: The largest portion, approximately 44.29%, will be sold by Suzhou MicroPort, a subsidiary of the Company, with the remainder coming from other existing shareholders.
- Consideration Structure: Tinavi will pay for the target assets by issuing new A-shares listed on the Shanghai Stock Exchange at an initial price of RMB 14.36 per share (subject to adjustments based on market conditions). The exact number of shares and the final consideration will be determined after an independent asset appraisal.
Details of the Transaction
- Parties Involved:
- Suzhou MicroPort (subsidiary of MicroPort Scientific, holding 82.29% in the Target Company)
- Other Target Company Shareholders (private equity and employee investment platforms)
- Tinavi Medical Technologies Co., Ltd.
- Assets Transferred: In total, 1,537,600,000 RMB registered capital representing 62% of the Target Company will be sold.
- Issue Price Adjustment Mechanism: The issue price of Tinavi shares may be adjusted once during a defined period if significant price movements in Tinavi shares or relevant market indices occur. The price will not be set below 80% of the average trading price for 20, 60, or 120 days before the adjustment date.
- Lock-Up Arrangements:
- Suzhou MicroPort: 36 months plus until after the Target Company achieves positive net profit and financials are publicly disclosed.
- Other Shareholders: Minimum 12 months (up to 36 months depending on when assets were acquired).
- Profit Attribution: All shareholders of Tinavi (existing and new) will be entitled to all undistributed profits as of the completion of the issuance, pro-rata to their holdings.
- Completion: Registration of the share transfer is expected within 30 working days after all conditions precedent are satisfied.
Strategic Rationale and Potential Impact
- Business Synergies: The Target Group has a strong track record in high-performance joint prostheses and established international marketing channels. Tinavi is a leader in orthopedic surgical robots. The transaction is expected to create powerful synergies, leveraging each party’s strengths to enhance efficiency, profitability, and resilience in the orthopedic sector.
- Financial Impact: Upon completion, the Target Company and its subsidiaries will cease to be consolidated as subsidiaries of MicroPort Scientific, which will retain a 38% stake. This may lead to a more optimized balance sheet and improved financial performance for MicroPort Scientific.
- Transaction Classification: The deal is expected to be a discloseable transaction under Chapter 14 of the Hong Kong Listing Rules, requiring reporting and announcement but not shareholders’ approval unless the final consideration changes the applicable percentage ratio.
- Uncertainty and Risks: The transaction is subject to several conditions, including internal approvals by Tinavi and the Target Company shareholders, as well as regulatory approvals from the Shanghai Stock Exchange and the China Securities Regulatory Commission. There is no guarantee that the transaction will proceed.
Financial Performance and Profile of the Target Company
- Scope of Business: Focuses on hip and knee orthopedic reconstruction, primarily in the US, Japan, and Europe. The Target Company’s medial pivot knee prosthesis is highly regarded, with a 17-year cumulative retention rate of 98.8% and a patient satisfaction rate of 95%.
- Financials:
- As of 31 March 2026: Total assets RMB 2,259.39 million; liabilities RMB 1,947.09 million; owner’s equity RMB 312.30 million.
- Loss before tax: RMB 78.83 million (2024), RMB 105.85 million (2025)
- Loss after tax: RMB 95.80 million (2024), RMB 104.73 million (2025)
About Tinavi Medical Technologies
- Tinavi is a leading PRC-based orthopedic surgical robotics company listed on the SSE. Its TiRobot series is widely used across China, with over 160,000 surgeries performed as of Q1 2026.
- The controlling shareholder is Mr. Zhang Songgen (23.42% equity, direct and indirect).
Summary and Shareholder Considerations
- This is a major strategic transaction for MicroPort Scientific, involving the partial divestment of a key overseas orthopedics asset and a partnership with one of China’s leading robotic surgery companies.
- The transaction could significantly alter the Company’s financial statements, risk exposure, and growth trajectory in the orthopedics sector.
- Shareholders and potential investors should be aware that the transaction’s completion is not guaranteed, as it remains subject to regulatory and corporate approvals and final price agreement after asset appraisal.
- The share issuance and asset sale structure could potentially impact the Company’s share price due to changes in earnings profile, asset composition, and future profit/loss reporting.
- All shareholders are strongly advised to exercise caution in dealing with the Company’s securities until further announcements clarify the transaction’s final terms and completion status.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. The transaction described is subject to regulatory and shareholder approval and may not proceed. Shareholders and potential investors should exercise caution and consult their own advisers before making any investment decisions based on this information.
【廣東話版】微創醫療科學有限公司擬出售上海微創骨科權益予天智航 — 投資者重要資訊詳解
重點摘要
- 潛在出售：微創醫療科學有限公司（港交所00853）擬將旗下子公司上海微創骨科有限公司（目標公司）62%股權出售予天智航醫療科技股份有限公司（上交所688277.SH，天智航）。
- 主要出售方：蘇州微創（微創醫療子公司）將出售約44.29%股權，其餘由其他現有股東提供。
- 對價方式：天智航將以發行A股新股支付，初始發行價每股人民幣14.36元（可根據市況調整），實際發行數量及最終對價待第三方資產評估後確定。
交易詳情
- 參與方：
- 蘇州微創（持有目標公司82.29%股權）
- 其他目標公司股東（私募基金、員工持股平台等）
- 天智航醫療科技股份有限公司
- 轉讓資產：合共1,537,600,000元人民幣註冊資本對應62%目標公司權益。
- 發行價調整機制：如天智航股價或相關指數有大幅波動，發行價可於特定期間內調整一次，調整後不低於調整基準日前20、60或120個交易日的平均價80%。
- 鎖定期安排：
- 蘇州微創：36個月及目標公司實現盈利並公開財報後方可轉讓。
- 其他股東：至少12個月（若持有資產不足12個月則鎖36個月）。
- 利潤分配：完成發行後，所有天智航新舊股東按持股比例享有累計未分配利潤。
- 完成期：所有先決條件達成後30個工作日內完成工商變更登記。
策略意義及潛在影響
- 業務協同：目標公司在高性能關節假體及海外渠道有深厚積累，天智航為骨科機器人龍頭。雙方預期強強聯手，提升規模、盈利能力及風險抵禦力。
- 財務影響：交易完成後，目標公司及其子公司不再納入微創醫療合併報表，微創保留38%權益，資產負債表有望優化，財務表現預期改善。
- 交易分類：預計構成港交所《上市規則》第14章需披露交易，暫時僅需公告無須股東大會批準（除非最終對價構成重大變動）。
- 風險提示：交易需獲天智航及目標公司股東內部批準，並經上交所及中國證監會審批，尚存不確定性。
目標公司財務與業務簡介
- 業務範圍：聚焦髖、膝關節重建，主要市場為美國、日本、歐洲。主打產品內側樞紐膝關節假體17年累計留存率98.8%，患者滿意度95%。
- 財務數據：
- 截至2026年3月31日：總資產22.59億元，負債19.47億元，淨資產3.12億元。
- 2024年稅前虧損0.79億元，稅後虧損0.96億元；2025年稅前虧損1.06億元，稅後虧損1.05億元。
天智航醫療科技簡介
- 天智航為國內骨科手術機器人行業領導者，產品覆蓋脊柱、關節及創傷三大領域，累計手術量超16萬例。
- 控股股東張松根先生（直接及間接持股23.42%）。
總結及股東須知
- 本次為微創醫療重大戰略調整，涉及海外骨科資產出售及與國內機器人龍頭合作。
- 交易完成可能對公司報表、行業佈局及未來盈利能力產生重大影響。
- 交易是否完成具不確定性，各方及監管機構批准後方可落實。
- 股份發行及資產出售可能導致公司價值、盈利結構及風險狀況變化，屬於股價敏感信息。
- 建議股東及投資者在最終條款及進展明朗前，審慎處理公司證券。
免責聲明：本文章僅供參考，並不構成投資建議。相關交易尚需監管部門及股東批准，最終能否完成存在不確定性。請股東及投資者於作出任何投資決定前諮詢專業意見，並審慎行事。
